



## Enanta Pharmaceuticals to Present at the Credit Suisse 25th Annual Healthcare Conference

October 26, 2016

### Presentation to be Webcast on November 7, 2016 at 1:30 P.M. MT

WATERTOWN, Mass.--(BUSINESS WIRE)--Oct. 26, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a presentation followed by a question and answer session with investors at the Credit Suisse 25<sup>th</sup> Annual Healthcare Conference on Monday, November 7 at 1:30 p.m. MT.

A live webcast and replay of the presentation will be accessible by visiting the "Calendar of Events" section on the "Investors" page of Enanta's website at [www.enanta.com](http://www.enanta.com). The webcast replay will be available following the conference and will be archived for approximately 30 days.

### About Enanta

Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. Enanta's research and development efforts are currently focused on four disease targets: Hepatitis C Virus (HCV), Hepatitis B Virus (HBV), Non-alcoholic Steatohepatitis (NASH) and Respiratory Syncytial Virus (RSV).

Enanta has discovered novel protease inhibitors and NS5A inhibitors that are members of the direct-acting-antiviral (DAA) inhibitor classes designed for use against the hepatitis C virus (HCV). Enanta's protease inhibitors, developed through its collaboration with AbbVie, include paritaprevir, which is contained in AbbVie's marketed DAA regimens for HCV, and glecaprevir (ABT-493), Enanta's second protease inhibitor, which AbbVie is developing in Phase 3 studies in combination with pibrentasvir (ABT-530), AbbVie's NS5A inhibitor. Enanta has also discovered a cyclophilin inhibitor, EDP-494, a novel host-targeting mechanism for HCV, which is now in a clinical proof-of-concept study in HCV patients, and EDP-305, an FXR agonist product candidate for NASH, currently in Phase 1 clinical development. Please visit [www.enanta.com](http://www.enanta.com) for more information on our programs and pipeline.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161026005092/en/>

Source: Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.  
Carol Miceli, 617-607-0710  
[cmiceli@enanta.com](mailto:cmiceli@enanta.com)